Status:

COMPLETED

Phase I, Dose Escalation Study of Decitabine

Lead Sponsor:

University of Florida

Collaborating Sponsors:

Hyundai Hope On Wheels

Conditions:

Leukemia, Lymphoblastic, Acute

Leukemia, Myeloid Acute

Eligibility:

All Genders

1-30 years

Phase:

PHASE1

Brief Summary

Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML). This study is based on the hypothesis tha...

Detailed Description

Decitabine is a hypomethylating agent with significant anti-leukemic effect in MDS and AML. Additionally, aberrant DNA methylation has been identified in high risk childhood ALL, and therefore, DNA hy...

Eligibility Criteria

Inclusion

  • Age: greater than 1 and less than 31 years of age;
  • Diagnosis: history of ALL, AML or MDS, currently in a complete remission (CR) following allo-HSCT (bone marrow leukemic blasts less than 5% by morphology), with high risk features including:
  • Status post allogeneic HSCT
  • GVHD prophylaxis:
  • Karnofsky or Lansky performance scores more than 50%. Karnofsky scores will be used for patients \> 16 years of age and Lansky scores for patients ≤ 16 years of age;
  • Platelet count ≥ 50,000 (untransfused);
  • Absolute neutrophil count ≥ 1000; and;
  • Hemoglobin ≥ 8 g/dL (un-transfused);

Exclusion

  • Progressive disease;
  • Philadelphia chromosome positive ALL (these patients receive tyrosine kinase inhibitor posttransplant);
  • Known hypersensitivity to any components of decitabine;
  • Uncontrolled grade 3-4 graft versus host disease;
  • Uncontrolled infection;
  • Serum creatinine \> 2 mg/dL or glomerular filtration rate (GFR) less than 60 mL/min/1.73m2 ;
  • Alanine Aminotransferase (ALT) greater than 3 times normal or serum total bilirubin greater than 2 mg/dL;

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 18 2018

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT02264873

Start Date

October 1 2014

End Date

September 18 2018

Last Update

October 15 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UF Health Shands Hospital

Gainesville, Florida, United States, 32610

Phase I, Dose Escalation Study of Decitabine | DecenTrialz